Health Canada clears trial of Lucid-MS in healthy volunteers | FSD Pharma will test a novel chemical treatment for all MS types
FSD Pharma will soon launch a first-in-human trial testing Lucid-21-302, known as Lucid-MS — its novel chemical treatment for multiple sclerosis (MS) — in healthy volunteers.
Health Canada has cleared the company to initiate a Phase 1 clinical trial of the investigational therapy, FSD Pharma announced in a press release.
The green light comes just a few weeks after the company submitted an application to the regulatory agency asking to start testing Lucid-MS in humans. The treatment had shown promise in animal models of the disease.
Lucid-MS is a new chemical entity proposed to treat all forms of MS. The upcoming study will first investigate the safety and tolerability of the compound in healthy people.
“We are excited to receive … regulatory clearance, and look forward to initiating the first clinical trial of this promising candidate as a critical steppingstone in our mission to develop novel therapeutics for the treatment